

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A longitudinal study of symptom burden in outpatients with advanced cancers based on Electronic Patient Reported Outcome (ePRO) platform: a single institution, prospective study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038223
Article Type:	Protocol
Date Submitted by the Author:	04-Mar-2020
Complete List of Authors:	Tang, Lili; Peking University Cancer Hospital, Department of Psycho-Oncology Pang, Ying; Peking University Cancer Hospital, Department of Psycho-Oncology He, Yi; Peking University Cancer Hospital, Department of Psycho-Oncology Shi, Qiuling; Chongqing Medical University, School of Public Health and Management Han, Xinkun; Peking University Cancer Hospital, Department of Psycho-Oncology Li, Zimeng; Peking University Cancer Hospital, Department of Psycho-Oncology Zhou, Chengcheng; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Xu; ePRO Vision (Beijing) Health Technology Co Ltd. Zhou, Yuhe; Peking University Cancer Hospital, Department of Psycho-Oncology He, Shuangzhi; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Yan; Peking University Cancer Hospital, Department of Psycho-Oncology Zhang, Yening; Peking University Cancer Hospital, Department of Psycho-Oncology Song, Lili; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Bingmei; Peking University Cancer Hospital, Department of Psycho-Oncology Li, Xiumin; Peking University Cancer Hospital, Department of Psycho-Oncology
Keywords:	Adult palliative care < PALLIATIVE CARE, Adult oncology < ONCOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A longitudinal study of symptom burden in outpatients with advanced cancers based on**
4 **Electronic Patient Reported Outcome (ePRO) platform: a single institution, prospective study**
5 **protocol**
6
7

8 Lili Tang^{1, *}, Ying Pang¹, Yi He¹, Qiuling Shi², Xinkun Han¹, Zimeng Li¹, Chengcheng Zhou¹,
9 Xu Wang³, Yuhe Zhou¹, Shuangzhi He¹, Yan Wang¹, Yening Zhang¹, Lili Song¹, Bingmei
10 Wang¹, Xiumin Li¹
11
12
13
14

15 * Corresponding author: Department of Psycho-oncology, Peking University
16 Cancer Hospital & Institute, Key laboratory of Carcinogenesis and Translational
17 Research (Ministry of Education), 52 Fucheng Road, Beijing, 100142, China. Fax: +86
18 10 88196648.
19
20
21
22

23 E-mail addresses: tanglili_cpos@126.com (LiLi Tang)
24
25
26
27

28 The first two authors contributed equally to this manuscript.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: A novel and brief electronic Patient Report Outcome (ePRO) Platform is needed in routine patient care in psycho-oncology clinic for implementing evidence-based symptom management in outpatients with advanced cancer. We describe the protocol for establishing the methodology and examining the dynamic changes of symptom burden by a single institution longitudinal study to provide critical parameters needed of implementing this ePRO platform for better symptom management.

Methods and analysis: The study focused on the advanced patients with lung cancer, stomach cancer, esophagus cancer, liver cancer, colorectal cancer or breast cancer. The study primary outcome focused on the study of symptom burden in advanced patients with fatigue, pain, insomnia, anxiety, depression, nausea and vomiting. The secondary outcomes included feasibility of using ePRO, symptom related QoL, reasons of no changes of symptom burden, defining frequency of PRO assessments and cut-points, items for screening, and management of comorbidity. The prospective study will monitor patient's symptom burden, physical and psychological health outcomes with the validated multi-symptom assessment tool MD Anderson Symptom Inventory (MDASI), and other PRO instruments (Insomnia Severity Index, Hospital Anxiety and Depression Scale, PHQ-9, and EQ5D5L). After initial outpatient visit for baseline assessment, ePRO system automatically pushes ePRO follow-up notification in weekly basis in 4 weeks (short message through mobile phone) to patients. The characteristics and changing trajectory of symptoms burden of outpatients with advanced cancer will be described. Parameters for using PROs, such as optimal time points for follow-up and cut-off point for alert will be determined. The feasibility of ePRO platform to track the changes of target symptoms in outpatients will be evaluated based on the completion rate, drop-

1
2
3
4 out rate, loss rate of follow-up and the reminder times of platform and research assistant.
5
6

7 **Ethics and dissemination:** The study protocol and related documents were approved by the
8
9
10 Institutional Research Board (IRB) of Peking University Cancer Hospital on 14 May 2019
11
12 (2019YJZ34). The manuscript is based on the latest protocol of Version 4.0, 30 June 2019
13
14

15 **RESULT:** This study will provide a rational synthesis of current methods and evidences for
16
17 using ePRO in psycho-oncology outpatient clinic.
18
19

20 **CONCLUSION:** The conclusion of this study will provide evidence to support the
21
22 implementation of ePRO platform in routine patient care. **Trial Registration:** chictr.org.cn
23
24 ChiCTR1900023560
25

26 **Key words:** advanced cancer, symptom management, outpatients, Electronic Patient Reported
27
28
29 Outcome, a longitudinal study
30
31
32
33
34
35

36 **There are several strengths and limitations of this study.**
37
38

- 39 ● The study is a prospective cohort study with a total of 7 follow-ups conducted within 4
40
41 weeks. It focuses on establishing a symptom management platform for outpatient ePRO and
42
43 obtain the dynamic symptoms trajectory of patients outside the hospital
44
45
46
- 47 ● Instead of a single tumor site, patients are recruited from six most common tumor sites: lung
48
49 cancer, gastric cancer, esophageal cancer, liver cancer, colorectal cancer, breast cancer.
50
51
52
- 53 ● PRO data are collected using an e-questionnaire based on WeChat, a major communication
54
55 app in China.
56
57
58
59
60

- 1
2
3
4 ● A group of questionnaires are used to measure the comprehensive well-being of patients,
5
6 mainly including MDASI-C, ISI, HADS, PHQ-9, EQ5D5L.
7
8
9
10 ● A relatively small sample size may be a limitation.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

According to the official report by the National Central Cancer Registry of China, cancer is the leading cause of death in China; there were 4.3 million newly diagnosed cancer cases and 2.8 million cancer deaths in 2015 in China. Lung cancer, gastric cancer, liver cancer, esophageal cancer and colorectal cancer ranked as the top five cancers in male, and breast cancer, lung cancer, gastric cancer, colorectal cancer and esophageal cancer rank as the top five cancers in female [1]. Cancer patients suffer from various symptoms due to the disease itself and treatment-related adverse reactions [2-4]. Studies have shown that one third of patients undergoing cancer treatments reported three or more moderate to severe symptoms [5]. The symptom burden of advanced cancer patients is even more serious.[4, 5] if the symptoms were not addressed properly in time, which will affect the quality of life and daily functions negatively and even shorten the survival period of patients.

In recent years, several studies have shown that good symptoms management based on patient-reported outcome (PRO) can benefit advanced cancer patients. For example, a single-centered study published in JAMA in 2017 showed that systematic symptom monitoring can significantly prolong the survival of patients by 5.2 months [6], which even achieved better results than most newly approved anti-cancer drugs in 2016. In 2019, a multi-centered study of Web-based follow-up of PRO symptoms demonstrated once again that this approach could bring survival benefits to patients.

[7]

However, there are few studies on effective symptom management of the cancer patients in routine patient care in China. The clinical doctors and nurses need a help for how to quickly capture the patient's dynamic change on symptom burden in patient's routine clinic appointment under the busy

1
2
3
4 working flow, and the patients also need an approach for reporting symptoms actively. A lot of the
5
6 symptom management were dealt with in the outpatient clinic, however, there is no existing
7
8 monitoring system on patients' status when they are out of the hospital.
9

10
11
12 In order to resolve this problem, we established an ePRO platform to monitor the symptom changes
13
14 when the patients left the clinic and go back home. The study is designed to monitor the changes of
15
16 the symptom burden through PROs, and symptom control practice among outpatients who self-
17
18 referred or referred by oncologists to clinic of department of psycho-oncology. With lack of
19
20 longitudinal data of physical, psychological, social symptom burden for Chinese oncology patients,
21
22 the proposed study aimed to include PROs of multiple symptom assessment tool, functioning
23
24 measure and HRQoL measure. Since there are many differences between the Chinese culture and
25
26 Western culture, the ePRO platform is also in different format. In Western countries, the electronic
27
28 application is mainly through e-mail, but e-mail was not widely used in Chinese population
29
30 especially in the elderly. We inserted the ePRO platform in the Wechat applet in mobile, for Wechat
31
32 is the most popular social networking app in China.
33
34
35
36
37
38
39
40

41 The purpose of this study is to describe the changes of the symptoms of outpatients and the impact
42
43 of the symptoms changes on the quality of life in patients, to determine the optimal times of follow-
44
45 up, the appropriate cut-off point of the alert thresholds for intervention. We also aim to examine the
46
47 experience, acceptance and compliance of patients with the ePRO platform, and to provide the
48
49 evidence for the platform to be used in clinical practice.
50
51
52
53
54
55
56
57

58 **METHODS AND ANALYSIS**

59
60

Study design

This is a real-world, ongoing, longitudinal single-centered prospective study with a total of 7 follow-ups conducted within 4 weeks after the first visit of the symptom management clinic. The flow chart of this study is shown in Figure 1.

Setting

This study was initiated by Department of Psycho-oncology In Peking University Cancer Hospital and started on June 2019 and is estimated to be completed before 31 March 2020. The site is the symptom management outpatient clinic in Peking University Cancer Hospital.

Study population and eligibility criteria

Patients are either self-referred or been professionally referred by oncologists in the institution for managing difficult pain or psychological symptoms. Eligible patients are required to be 1) Over 18 years of age; 2) fluency in Chinese; 3) a confirmed diagnosis of advanced lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer and breast cancer. Exclusion criteria included 1) a history of major severe mental disorders, unable to cooperate with the investigator; 2) poor physical condition, judged by the attending physician, not suitable for participating in the study; 3) being not able to use ePRO platform.

Study objectives

1
2
3
4 The primary objective is systemic monitoring changes of target symptoms (including fatigue,
5
6 insomnia, anxiety, depression, nausea and vomiting) in patients with advanced cancer in the
7
8 symptom management clinic of Peking University cancer hospital during a systematic follow-up
9
10 within 4 weeks.
11
12

13
14
15 The second objectives are as follow:
16

- 17
18 (1) Evaluating the feasibility of tracking changes in target symptoms in outpatients through the
19
20 ePRO follow-up system.
21
22
23 (2) Observing the improvement of quality of life in patients seeking symptom management in
24
25 Department of Psycho-Oncology within 4 weeks after initial visiting.
26
27
28 (3) Finding out the reasons why the symptoms of outpatients cannot be improved within 4 weeks
29
30 after the first visiting through a qualitative research.
31
32
33 (4) Determining the appropriate frequency of PRO symptom screening through the description and
34
35 analysis of the changes in patients' symptoms during the 4-week follow-up after initial visiting.
36
37
38 (5) Determining the alert score of each PRO symptom through the analysis of the symptom
39
40 changes during the follow-up 4 weeks after initial visiting.
41
42
43 (6) Exploring the most appropriate PRO items for the targeted symptoms of the screening.
44
45
46 (7) Analyzing the effects of co-morbidity and chronic diseases on symptom burden and symptom
47
48 management of cancer patients.
49
50
51
52
53
54

55 **Withdrawal criteria**
56
57
58
59
60

1
2
3
4 Patients undergo a brief interview with a research assistant to identify the following exclusion
5
6 criteria: (1) major communication difficulties; (2) inability to commit to the required 7 follow-up
7
8 PRO (i.e., too ill to participate); (3) cognitive impairment;(4) those who do not follow the study
9
10 protocol (deliberately providing incorrect PRO data) ;(5) those who ask to withdraw from the
11
12 research or (6) other conditions that require withdrawal as assessed by the investigator
13
14
15
16
17
18
19
20

21 **Outcomes**

22 Primary Outcomes

23
24
25
26
27 The primary outcomes are the improvement on the intensity of the patients' target symptoms and
28
29 the PRO impact of target symptoms on patient's life in 4 weeks after the initial visiting.
30
31
32

33 Secondary Outcomes

34
35
36 The second outcomes include as follow:
37
38
39

- 40 (1) Feasibility of tracking patients' symptoms with ePRO which contains two feasibility indexes:
41
42 1) At least 50% of patients completed self-report within 24 hours after being sent the follow-up
43
44 message; more than 70% of patients completed self-report within 24 hours after being called;
45
46 at least 70% of patients complete all self-reports within 4 weeks.
47
48
49 2) The percentage of patients who met the eligibility criteria agreed to participate in the study is
50
51 80%.
52
53
54
55 (2) Determining the changing trends of target symptoms intensity and their impact on quality of
56
57 life over a 4-week period.
58
59
60

- (3) Semi-structured interviews were conducted with patients whose symptom improvement score was less than 2 points after 4 weeks, and the causes of uncontrolled symptoms were analyzed.
- (4) Determining the appropriate frequency of PRO screening for different symptoms with the method of looking for significant changes in PRO scores (such as using generalized mixed effect model).
- (5) Determining the alert scores of PRO screening for different symptoms with clinical significance were determined by the criterion validity (such as EQ-5D) using the regression analysis model.

PRO instruments, Data collection, management and monitoring

Totally 9 data collection instruments were used in this study,

- (1) MD Anderson Symptom Inventory, MDASI.

MDASI^{[8][9]} is a widely used symptom inventory with 19 items (13 items for symptom severity, 6 items for life interference), 0=Nothing, 10=Most severity. Psychometric study has revealed that the Chinese version of MDASI has good reliability and validity, which has showed that MDASI is feasible to be used to measure the severity of multiple symptoms and their impact on function in Chinese cancer patients. Moreover, we have added 5 more items for specific cancer sites in our study to capture these special characteristics: “constipation” and “cough” for lung cancer; “dysphagia for gastrointestinal cancer”; “hot flashes and upper extremity edema for breast cancer”.

A single “quality of life” item was used to anchor this study.

1
2
3
4 (2) Insomnia Severity Index, ISI
5
6

7 It is a validated scale for measuring insomnia severity in the last two weeks. There are total 7 items,
8
9 0-4 score for each item, with the sum score of 0-28. 0-7 score indicates no insomnia; 8-14 score
10
11 indicates subclinical insomnia; 15-21 score indicates moderate insomnia, 22-28 score indicates
12
13 severe insomnia. Simplified Chinese version of ISI has been validated by Lin et al ^[10].
14
15
16

17
18 (3) Hospital Anxiety and Depression Scale, HADS
19
20

21 HADS has 14 items with a score spectrum of 0-4 for each item, which is used to measure the anxiety
22
23 and depression for the patients in the past week. It is more used for patients with somatic symptoms
24
25 in the general hospitals with good reliability and validity and recommended to used for patients with
26
27 advanced cancer or receiving palliative care ^[11].
28
29
30

31
32 (4) 9 Item Patient Health Questionnaire, PHQ-9
33
34

35 PHQ-9 is used to evaluate the depression of patients in the past two weeks. The score spectrum of
36
37 symptoms severity is from 0=none at all to 3=almost every day, and the total score was from 0-27.
38
39 Depression can be considered when the sum score is ≥ 10 . Simplified Chinese version of PHQ-9
40
41 has a good validation ^[12].
42
43

44 (5) EuroQol Five Dimensions questionnaire-5L version, EQ-5D-5L
45
46

47 EQ-5D-5L is a multidimensional measurement for health-related quality of life, which contains
48
49 these five domain to describe patients' health: 1) mobility; 2) self-care; 3) usual activities; 4)
50
51 pain/discomfort; 5) anxiety/depression, with a scale from 0=No difficulty to 4=extremely
52
53 difficulty ^{[13][14]}
54

55 (6) Distress Thermometer, DT
56
57

58 DT is recommended by NCCN in the distress management guideline and has been introduced to
59
60 China from 2007. DT has only one item with a scale from 0=No distress to 10=extremely distress.

1
2
3
4 Problem list including 5 domains: practical problem, communication problem, emotion problem,
5 physical problem, spirit and religion problem. It is recognized as the briefest tool for distress
6 screening, especially in busy oncology clinical practice [15].
7
8

9
10 (7) General demographic and disease data. General demographic data includes age, sex,
11 occupation, etc. The latter includes disease diagnosis, staging, treatment, medication, etc.
12
13

14
15 (8) ECOG score. This is a health tool that evaluates cancer patient functional status and clinically
16 stratifies these patients' ability to tolerate therapies, which runs from 0 to 5, with 0 denoting
17 perfect health and 5 death [16].
18
19

20
21 (9) Charlson Comorbidity Index. Comorbid conditions are best evaluated with use of the Charlson
22 Comorbidity Index. Many studies have shown that the impact of comorbidities is significant on the
23 survival outcomes and prognosis of cancer patients. Here are the conditions used in the
24 comorbidity and the number of points they are awarded: score of 1 for myocardial infarction,
25 congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic
26 obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and diabetes
27 mellitus (in terms of diabetes mellitus, score of 1 for uncomplicated and 2 for end organ damage);
28 score of 2 for moderate to severe chronic kidney disease, hemiplegia, leukemia, malignant
29 lymphoma, solid tumor (2 in case of presence and 6 in case tumor is metastatic), liver disease (mild
30 1 point, moderate to severe 3 points) and AIDS [17].
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 PRO data are collected using an ePRO platform. ePROhub™ is dedicated on ePRO clinical
49 research on patient's data collection, assessment and management launched by ePRO Vision
50 (Beijing) Health Technology Co Ltd. in 2018. The platform consist of ePROcell™ and ePROhub™
51 two parts. Smartphone-based client, ePROcell™, is for patient's ePRO reporting and clinician's
52 ePRO data management, intervention and project management. ePROhub™ platform, the EDC
53
54
55
56
57
58
59
60

1
2
3
4 (electronic data capture) complied, is the cloud based symptom, management platform to store
5
6 and assess patient's data, support clinicians manage patient's data and intervention activities
7
8
9 with AI (artificial intelligence) capability, output data to other database platform for further data
10
11 processing. Figure 2 shown below gives total picture in Peking University Cancer Hospital project
12
13 case.
14
15

16
17 ePROcell™ is fully integrated with internet-based WeChat, the most popular and the biggest
18 social network application in China, to maximize WeChat's advantages of world-class user
19 experience and massive population coverage into ePRO practice enable ePRO data collection-
20 and management happening anywhere and anytime is possible. The pre-register patients can
21 easy click the landscape-screen to answer relevant questionnaires and sending back to clinicians
22 via cloud-based ePROhub™. The e-informed consent and e-signature is implemented before-
23 and after reporting to secure ePRO data effectiveness and integrity. The pre-defined threshold of
24 server symptom plus triage process support clinician efficiently communicate with patients via
25 ePROcell™ when e-alert and e-reminder occurred.
26
27

28
29 According to the pre-defined schedule, ePROcell™ automatically send out reminder message to
30 patients during the reporting-day, and confirmation message after patient submit. With PRO-
31 calendar and PRO management from ePROcell™, clinicians could easily review- and manage
32 project progress anytime to secure data quality, reporting progress and project quality. The
33 ePROcell™ frequently visit patient's and clinical data stored in ePROhub™ and integrated
34 backend database platform to support clinicians' regular patient's symptom following up and
35 symptom management activities, which is the most efficient way to deliver effective symptom
36 intervention and routine care with desired data-driven patient-centered care.
37
38

39
40 The cloud-based ePROhub™, located in hospital's datacenter, is the data management platform
41 and has dedicated data communication channel with the backend database platform REDCap,
42 the US free of Charge SQL database platform, via it's API (Application Program Interface) to
43 synchronize pre-defined clinical data, like CRF (case report form) and scale, and patient's ePRO
44 data. The output data could be converted to professional statistics program, like SAS or SPSS,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 with standard data format for their final data analysis. All data are deidentified and stored in the
5
6 REDCap platform. Data monitoring is carried out regularly by the IRB of Peking University Cancer
7
8 Hospital.
9

10 11 12 13 **Quality control**

14
15
16 Investigators received standard operating procedure training before recruiting the patients.
17
18

19 20 21 **Sample size calculation**

22
23 We will use the group-based trajectory model (GBTM) to identify subgroups with distinct
24
25 trajectories of symptom development during the 4 week of investigation. Previous studies showed
26
27 that about 30% of patients with advanced lung cancer reported higher symptom burden than the
28
29 others. (ref: Cleeland CS et al. Levels of symptom burden during chemotherapy for advanced lung
30
31 cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011 Jul
32
33 20;29(21):2859-65.). To obtain a 95% confidence interval as 22%-38%, we will need 148
34
35 evaluable patients. Considering a 20% attrition, we will recruit 185 patients.
36
37
38
39
40

41 42 **Data analysis**

43
44 For inclusion in the final analysis, at least the baseline assessment and one successful follow-up is
45
46 required. The last observation carried forward imputation method will be used to impute missing
47
48 data. We will conduct a sensitive analysis to exam whether the symptom burden of the complete
49
50 cases is significantly different from that of cases with missing.
51
52

53
54
55 Continuous data will be described as mean \pm SD while categorical data will be described as
56
57 number and percentage. The changing trends of target symptoms intensity over time will be
58
59
60

1
2
3
4 presented by line charts. The improvement on the intensity of the patients' target symptoms and
5
6 the PRO impact of target symptoms on patient's life in 4 weeks after the initial visiting will be
7
8 analyzed by general linear mixed model, while the appropriate frequency of ePRO screening for
9
10 different symptoms will be determined according to significant change point of ePRO score. The
11
12 impact of target symptoms intensity on quality of life, the alert value of each symptom and, most
13
14 appropriate PRO items for the targeted symptoms of the screening and the effects of co-morbidity
15
16 and chronic diseases on symptom burden and symptom management will be analyzed by
17
18 regression models. Differences are considered statistically significant if the two-tailed p values of
19
20 <0.05. All quantitative data analysis will be performed using R 3.6.1 and Python 3.7.4, while the
21
22 transcription of qualitative interview will be coded and analyzed using NVivo 11.0.
23
24
25
26
27
28
29
30
31
32
33

34 **Patient and public involvement**

35
36
37 Patients and the general public were not involved in the design, recruitment and implementation of
38
39 the study. We have no plans of informing the study participants regarding the results of this study.
40
41
42 However, the results will be disseminated to the applicants in the form of a published article as
43
44 requested.
45
46
47
48
49
50

51 **ETHICS AND DISSEMINATION**

52
53
54 The protocol is registered and any amendments to the research protocol will be submitted for IRB
55
56 approval. The results in this study will be first reported at relevant medical conferences and then
57
58 will eventually be published in peer-reviewed journals.
59
60

Author Affiliations

¹ Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China

² School of Public Health and Management, Chongqing Medical University, Chongqing, China

³ ePRO Vision Health Technology Co. Ltd., Beijing, China

Contributors LT, YP, YH and QS contributed to the study design. LT, YP, YH, XH, ZL, CZ, XW, YZ, SH, YW, YZ, LS, BW, XL performed the study. YP, YH, XH, ZL, CZ, XW drafted the initial manuscript. LT and QS revised the draft. All authors have reviewed and approved the final manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was approved by the (IRB) of Peking University Cancer Hospital on 14 May 2019 (2019YJZ34).

ORCID ID

Lili Tang <https://orcid.org/0000-0003-1524-4617>

References

- [1] Chen W , Zheng R , Baade P D , et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
- [2]. Reilly C M, Deborah Watkins Bruner, Sandra A. Mitchell, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment[J]. Supportive Care in Cancer, 2013, 21(6):1525-1550.
- [3]. Dantzer, Robert, Meagher, Mary W, Cleeland, Charles S. Translational approaches to treatment-induced symptoms in cancer patients[J]. Nature Reviews Clinical Oncology, 9(7):414-426.
- [4]. Henry D H , Viswanathan H N , Elkin E P , et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.[J]. Supportive Care in Cancer, 2008, 16(7):791-801.
- [5]. Cleeland, C S, Fengmin Zhao, Victor T. Chang, et al., The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer, 2013. 119(24): p. 4333-40.
- [6]. Basch, E, Deal A M, Dueck A C, et al., Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA, 2017. 318(2):197-198.

- 1
2
3
4 [7]. Denis F , Basch E , Septans A L , et al. Two-Year Survival Comparing Web-Based Symptom
5
6 Monitoring vs Routine Surveillance Following Treatment for Lung Cancer[J]. JAMA, 2019,
7
8 321(3):306-307.
9
10
11
12 [8].Cleeland C S , Mendoza T R , Wang X S , et al. Assessing symptom distress in cancer
13
14 patients : The M. D. Anderson Symptom Inventory. Cancer, 2000, 89(7):1634-1646.
15
16
17 [9].Xin, Shelley, Wang, et al. Chinese version of the M. D. Anderson Symptom Inventory :
18
19 Validation and application of symptom measurement in cancer patients[J]. Cancer, 2004.
20
21
22 [10].Lin R M , Xie S S , Yan W J , et al. Factor structure and psychometric properties of the
23
24 Insomnia Severity Index in Mainland China. Social Behavior and Personality: an international
25
26 journal, 2018, 46(2).
27
28
29 [11].Guo Hua Z , Ming Zhi X U . Factorial Structure of the Hospital Anxiety and Depression
30
31 Scale in Outpatients with Somatic Disease. Chinese Journal of Clinical Psychology. 2006,
32
33 14(6):591-592.
34
35
36 [12].Chen S , Fang Y , Psych H C F , et al. Validation of the nine-item Patient Health
37
38 Questionnaire to screen for major depression in a Chinese primary care population. Asia Pac
39
40 Psychiatry. 2013,5(2):61-68.
41
42
43 [13].Luo N , Liu G , Li M , et al. Estimating an EQ-5D-5L Value Set for China. Value in Health,
44
45 2017, 20(4):662-669.
46
47
48 [14].Liu L , Li S , Wang M , et al. Comparison of EQ-5D-5L health state utilities using four
49
50 country-specific tariffs on a breast cancer patient sample in mainland China. Patient Preference &
51
52
53
54
55
56
57
58
59
60


1
2
3
4 Adherence, 2017, 11:1049-1056.].
5
6

7 [15].Tang L, Zhang Y, Pang Y, et al. Validation and Reliability of Distress Thermometer in
8
9

10 Chinese Cancer Patients. Chin J Cancer Res. 2011,23(1):54-58.
11
12

13 [16].Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity
14
15 and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-
16
17
18 55.
19
20

21 [17].Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
22
23 comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-
24
25
26
27 83.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 The flow chart of this study

90x99mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Peking University Cancer Hospital project case
160x59mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Check
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	✓
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	✓
	2b	All items from the World Health Organization Trial Registration Data Set	✓
Protocol version	3	Date and version identifier	✓
Funding	4	Sources and types of financial, material, and other support	NA
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	✓
	5b	Name and contact information for the trial sponsor	NA
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	NA
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	✓
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	✓
	6b	Explanation for choice of comparators	NA
Objectives	7	Specific objectives or hypotheses	✓
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	✓

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	✓
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	✓
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	NA
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	NA
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	✓
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	✓
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	✓
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	✓

Methods: Assignment of interventions (for controlled trials)**NA**

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	--

1				
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
4	mechanism		describing any steps to conceal the sequence until interventions are	
5			assigned	
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13		17b	If blinded, circumstances under which unblinding is permissible, and	
14			procedure for revealing a participant's allocated intervention during	
15			the trial	
16				
17				
18				
19				
20	Methods: Data collection, management, and analysis			
21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	✓
22	methods		trial data, including any related processes to promote data quality (eg,	
23			duplicate measurements, training of assessors) and a description of	
24			study instruments (eg, questionnaires, laboratory tests) along with	
25			their reliability and validity, if known. Reference to where data	
26			collection forms can be found, if not in the protocol	
27		18b	Plans to promote participant retention and complete follow-up,	✓
28			including list of any outcome data to be collected for participants who	
29			discontinue or deviate from intervention protocols	
30	Data	19	Plans for data entry, coding, security, and storage, including any	✓
31	management		related processes to promote data quality (eg, double data entry;	
32			range checks for data values). Reference to where details of data	
33			management procedures can be found, if not in the protocol	
34	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	✓
35	methods		Reference to where other details of the statistical analysis plan can be	
36			found, if not in the protocol	
37		20b	Methods for any additional analyses (eg, subgroup and adjusted	✓
38			analyses)	
39		20c	Definition of analysis population relating to protocol non-adherence	✓
40			(eg, as randomised analysis), and any statistical methods to handle	
41			missing data (eg, multiple imputation)	
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52	Methods: Monitoring			
53	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	✓
54			and reporting structure; statement of whether it is independent from	
55			the sponsor and competing interests; and reference to where further	
56			details about its charter can be found, if not in the protocol.	
57			Alternatively, an explanation of why a DMC is not needed	
58				
59				
60				

1				
2		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
3				
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	NA
7				
8				
9				
10				
11	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA
12				
13				
14				

Ethics and dissemination

15				
16				
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	✓
18				
19				
20				
21	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	✓
22				
23				
24				
25				
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	✓
27				
28				
29				
30		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
31				
32				
33	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	✓
34				
35				
36				
37	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	✓
38				
39				
40	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	✓
41				
42				
43				
44				
45	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
46				
47				
48	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	✓
49				
50				
51				
52				
53				
54		31b	Authorship eligibility guidelines and any intended use of professional writers	✓
55				
56				
57		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	✓
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

A longitudinal study of symptom burden in outpatients with advanced cancers based on Electronic Patient Reported Outcome (ePRO) platform: a single institution, prospective study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038223.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Jul-2020
Complete List of Authors:	Tang, Lili; Peking University Cancer Hospital, Department of Psycho-Oncology Pang, Ying; Peking University Cancer Hospital, Department of Psycho-Oncology He, Yi; Peking University Cancer Hospital, Department of Psycho-Oncology Shi, Qiuling; Chongqing Medical University, School of Public Health and Management Han, Xinkun; Peking University Cancer Hospital, Department of Psycho-Oncology Li, Zimeng; Peking University Cancer Hospital, Department of Psycho-Oncology Zhou, Chengcheng; Peking University Cancer Hospital, Department of Psycho-Oncology Zhou, Yuhe; Peking University Cancer Hospital, Department of Psycho-Oncology He, Shuangzhi; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Yan; Peking University Cancer Hospital, Department of Psycho-Oncology Zhang, Yening; Peking University Cancer Hospital, Department of Psycho-Oncology Song, Lili; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Bingmei; Peking University Cancer Hospital, Department of Psycho-Oncology Li, Xiumin; Peking University Cancer Hospital, Department of Psycho-Oncology
Primary Subject Heading:	Palliative care
Secondary Subject Heading:	Oncology
Keywords:	Adult palliative care < PALLIATIVE CARE, Adult oncology < ONCOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A longitudinal study of symptom burden in outpatients with advanced cancers based on**
4 **Electronic Patient Reported Outcome (ePRO) platform: a single institution, prospective**
5 **study protocol**
6
7

8 Lili Tang ^{1, *}, Ying Pang ¹, Yi He ¹, Qiuling Shi ², Xinkun Han ¹, Zimeng Li ¹, Chengcheng Zhou ¹,
9 Yuhe Zhou ¹, Shuangzhi He ¹, Yan Wang ¹, Yening Zhang ¹, Lili Song ¹, Bingmei Wang ¹,
10 Xiumin Li ¹
11
12
13
14

15 * Corresponding author: Department of Psycho-oncology, Peking University Cancer
16 Hospital & Institute, Key laboratory of Carcinogenesis and Translational Research
17 (Ministry of Education), 52 Fucheng Road, Beijing, 100142, China. Fax: +86 10
18 88196648.
19
20
21
22

23 E-mail addresses: tanglili_cpos@126.com (LiLi Tang)
24
25
26
27

28 The first two authors contributed equally to this manuscript.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: A novel and brief electronic Patient Report Outcome (ePRO) Platform is needed for implementing evidence-based symptom management in outpatients with advanced cancer. We describe the protocol for establishing the methodology for measuring symptom burden, and for then to provide critical parameters needed to implement better symptom management on the ePRO platform.

Methods and analysis: The study focuses on the patients with advanced lung cancer, stomach cancer, esophagus cancer, liver cancer, colorectal cancer or breast cancer. The primary outcome is the changes of symptom burden, The study will prospectively monitor patient's symptom burden, physical and psychological outcomes with MD Anderson Symptom Inventory (MDASI), and other PRO instruments (ISI, HADS, PHQ-9, and EQ5D5L).The secondary outcomes include feasibility of using ePRO, symptom related QoL, reasons for no changes of symptom burden, defining frequency of PRO assessments and cut-points, items for screening, and management of comorbidity. After initial outpatient visit for baseline assessment, ePRO system automatically sends ePRO follow-up notification weekly for 4 weeks to patients. The characteristics and changing trajectory of symptoms burden of outpatients with advanced cancer will be described. Parameters for using PROs, such as optimal time points for follow-up and cut-off point for alert will be determined. The feasibility of ePRO platform to track the changes of target symptoms in outpatients will be evaluated.

Ethics and dissemination: The study protocol and related documents were approved by the Institutional Research Board (IRB) of Peking University Cancer Hospital on 14 May 2019

1
2
3
4 (2019YJZ34). The manuscript is based on the latest protocol of Version 4.0, 30 June 2019. The
5
6 results of this study will be disseminated through academic workshops, peer-reviewed
7
8 publications and conferences.
9

10
11
12 **RESULT:** The study will provide data to guide the development and implementation of ePRO for
13
14
15 psycho oncology.
16

17
18 **Trial Registration:** chictr.org.cn ChiCTR1900023560
19

20
21 **Key words:** advanced cancer, symptom management, out-patients, Electronic Patient Reported
22
23 Outcome, a longitudinal study
24
25

26
27
28
29
30 **There are several strengths and limitations of this study.**
31

- 32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- The study is a prospective cohort study with a total of 7 follow-ups conducted within 4 weeks. It focuses on establishing a symptom management platform for outpatient ePRO and obtain the dynamic symptoms trajectory of patients outside the hospital
 - Instead of a single tumor site, the six most common tumor sites are represented: lung cancer, gastric cancer, esophageal cancer, liver cancer, colorectal cancer, breast cancer.
 - PRO data are collected using an e-questionnaire based on WeChat, a major communication app in China.
 - A group of questionnaires are used to measure the comprehensive well-being of patients, mainly including MDASI-C, ISI, HADS, PHQ-9 and EQ5D5L.

INTRODUCTION

According to the official report by the National Central Cancer Registry of China, cancer is the leading cause of death in China; there were 4.3 million newly diagnosed cancer cases and 2.8 million cancer deaths in 2015 in China. Lung cancer, gastric cancer, liver cancer, esophageal cancer and colorectal cancer rank as the top five cancers in men, and breast cancer, lung cancer, gastric cancer, colorectal cancer and esophageal cancer rank as the top five cancers in women [1]. Cancer patients suffer from various symptoms due to the disease itself and treatment-related adverse reactions [2-4]. Studies have shown that one third of patients undergoing cancer treatments reported three or more moderate to severe symptoms [5]. The symptom burden of advanced cancer patients is even more serious.[4, 5] if the symptoms were not addressed properly in time, which will affect the quality of life and daily functions negatively and even shorten the survival period of patients.

In recent years, several studies have shown that good symptom management based on patient-reported outcome (PRO) can benefit advanced cancer patients. For example, a single-centered study published in JAMA in 2017 showed that systematic symptom monitoring can significantly prolong the survival of patients by 5.2 months [6], which even achieved better results than most newly approved anti-cancer drugs in 2016. In 2019, a multi-centered study of Web-based follow-up of PRO symptoms demonstrated once again that this approach could bring survival benefits to patients. [7]

However, there are few studies on effective symptom management of the cancer patients in routine patient care in China. The clinical doctors and nurses need a help for how to quickly capture the patient's dynamic change on symptom burden in patient's routine clinic appointment

1
2
3
4 under the busy working flow, and the patients also need an approach for reporting symptoms
5
6 actively. A lot of the symptom management are dealt with in the outpatient clinic, however, there
7
8 is no monitoring system on patients' status when they are out of the hospital.
9

10
11
12 In order to resolve this problem, we have established an ePRO platform to monitor the symptom
13
14 changes when the patients have left the clinic and gone back home. The platform is designed to
15
16 monitor the changes of the symptom burden through PROs among outpatients. With lack of
17
18 longitudinal data of physical, psychological, social symptom burden for Chinese oncology
19
20 patients, the proposed study aimed to include PROs of multiple symptom assessment tool,
21
22 functioning measure and HRQoL measure. Since there are many differences between the Chinese
23
24 culture and Western culture, the ePRO platform is also in different format. In Western countries,
25
26 some of the electronic applications are through e-mail, but e-mail is not widely used in Chinese
27
28 population especially by the elderly. We inserted the ePRO platform in the Wechat applet in
29
30 mobile, for Wechat is the most popular social networking app in China. It was reported the
31
32 popularization rate of Wechat in China in 2018 was 87.3%, and according to our experiences,
33
34 most of our patients, even the elderly can use Wechat.
35
36
37
38
39
40
41
42
43

44 The purpose of this study is to describe the changes of the target symptoms (pain, insomnia,
45
46 fatigue, anxiety, depression, nausea and vomiting) of outpatients within 4 weeks after their first
47
48 visit in the symptom management clinic and to test the feasibility to track patients' symptom
49
50 changes through ePRO platform, to examine the impact of symptom changes on quality of life, to
51
52 explore the causes of uncontrolled symptoms within four weeks; to determine the appropriate
53
54 frequency, PRO items and alert score of PRO screening for different symptoms; to analyze the
55
56 effects of co-morbidity and chronic diseases on symptom burden and symptom management of
57
58
59
60

1
2
3
4 cancer patients.
5
6

7 **METHODS AND ANALYSIS**

8
9

10 **Study design**

11
12
13 This is a real-world, ongoing, longitudinal single-center prospective study with a total of 7
14
15 follow-ups conducted within 4 weeks after the first visit of the symptom management clinic (on
16
17 Day 1, Day 3, Day 7, Day 10, Day 14, Day 21 and Day 28). The flow chart of this study is shown
18
19 in Figure 1(Figure 1: The flow chart of this study). After the last follow-up, a semi-structured
20
21 interview will be conducted with patients whose symptom scores worsen or improved less than 2
22
23 points after 4 weeks.
24
25
26
27
28
29
30
31

32 **Setting**

33
34
35 This study was initiated by Department of Psycho-oncology In Peking University Cancer Hospital
36
37 and started on June 2019 and is estimated to be completed before 31 March 2020. The site is the
38
39 symptom management outpatient clinic in Peking University Cancer Hospital.
40
41
42
43
44
45
46

47 **Study population and eligibility criteria and recruitment**

48
49

50 Patients who visit the symptom management clinic for managing difficult pain or psychological
51
52 symptoms. Most of the patients are recommended by their oncologist, some patients were
53
54 recommended by other patients who had been treated in this clinic, while some patients saw
55
56 advertisement of this clinic. Those patients include both patients undergoing active treatment for
57
58
59
60

1
2
3
4 cancer and patients only having palliative symptomatic management. Eligible patients are required
5
6 to be 1) Over 18 years of age; 2) fluency in Chinese; 3) a confirmed diagnosis of advanced lung
7
8 cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer and breast cancer.

9
10
11 Exclusion criteria include 1) a history of major severe mental disorders, unable to cooperate with
12
13 the investigator; 2) poor physical condition, judged by the attending physician, not suitable for
14
15 participating in the study; 3) being not able to use ePRO platform.
16
17

18
19
20 All the eligible patients who visit the symptom management clinic at the first time will be invited
21
22 to participant in this study by the doctors in this clinic. If the patients are interested in this study, a
23
24 research assistant will inform this study to patients in detail and get their written inform consent.
25
26
27

28 29 30 31 32 **Study objectives**

33
34
35 The primary objective is systemic monitoring changes of target symptoms (including pain, fatigue,
36
37 insomnia, anxiety, depression, nausea and vomiting) in patients with advanced cancer in the
38
39 symptom management clinic of Peking University cancer hospital during a systematic follow-up
40
41 within 4 weeks.
42
43
44

45
46 The second objectives are as follow:
47

- 48
49 (1) Evaluating the feasibility of tracking changes in target symptoms in outpatients through the
50
51 ePRO follow-up system.
52
53
54 (2) Observing the improvement of quality of life in patients seeking symptom management in
55
56 Department of Psycho-Oncology within 4 weeks after initial visiting.
57
58
59 (3) Finding out the reasons why the symptoms of outpatients cannot be improved within 4 weeks
60

1
2
3
4 after the first visiting through a qualitative research.
5

- 6
7 (4) Determining the appropriate frequency of PRO symptom screening through the description
8
9 and analysis of the changes in patients' symptoms during the 4-week follow-up after initial
10
11 visiting.
12
13
14 (5) Exploring the most appropriate PRO items for the targeted symptoms of the screening.
15
16
17 (6) Determining the alert score of each PRO symptom through the analysis of the symptom
18
19 changes during the follow-up 4 weeks after initial visiting.
20
21
22 (7) Analyzing the effects of co-morbidity and chronic diseases on symptom burden and symptom
23
24 management of cancer patients.
25
26
27
28
29

30 **Withdrawal criteria**

31
32
33 Patients undergo a brief interview with a research assistant to identify the following exclusion
34
35 criteria: (1) major communication difficulties; (2) inability to commit to the required 7 follow-up
36
37 PRO (i.e., too ill to participate); (3) cognitive impairment;(4) those who do not follow the study
38
39 protocol (deliberately providing incorrect PRO data) ;(5) those who ask to withdraw from the
40
41
42 research or (6) other conditions that require withdrawal as assessed by the investigator
43
44
45
46
47
48
49

50 **Outcomes**

51 **Primary Outcomes**

52
53
54
55
56
57 The primary outcomes are the changes on the intensity of the patients' target symptoms (including
58
59 pain, fatigue, insomnia, anxiety, depression, nausea and vomiting) in 4 weeks after the first
60

1
2
3
4 visiting.
5
6
7
8
9

10 Secondary Outcomes

11
12
13 The second outcomes include as follow:

14
15
16
17 (1) Feasibility of tracking patients' symptoms with ePRO which contains two feasibility indexes:

18
19
20 1) At least 50% of patients completed self-report within 24 hours after being sent the follow-up
21
22 message; more than 70% of patients completed self-report within 24 hours after being called;
23
24 at least 70% of patients complete all self-reports within 4 weeks.

25
26
27 2) The percentage of patients who met the eligibility criteria agreed to participate in the study is
28
29 80%.

30
31
32 (2) The impact of changing trends of target symptoms intensity on quality of life over a 4-week
33
34 period.

35
36
37 (3) The causes of uncontrolled symptoms within 4 weeks.

38
39
40 (4) The appropriate frequency of PRO screening for different symptoms with the method of
41
42 looking for significant changes in PRO scores (such as using generalized mixed effect
43
44 model).

45
46
47
48 (5) The most appropriate PRO items for the targeted symptoms of the screening, with the
49
50 optimal reliability and validity.

51
52
53 (6) The alert scores of PRO screening for different symptoms with clinical significance were
54
55 determined by the criterion validity (such as EQ-5D) using the regression analysis model.
56
57
58
59
60

- 1
2
3
4 (7) The effects of co-morbidity and chronic diseases on symptom burden and symptom
5
6 management of cancer patients.
7
8
9

10
11 **Study instruments, Data collection, management and monitoring, qualitative interview**
12
13

14
15 **Totally 9 study instruments are used in this study, including 6 PRO instruments.**
16

17
18 (1) PRO instruments
19

20
21 *MD Anderson Symptom Inventory, MDASI.*
22

23
24 MDASI [8][9] is a widely used symptom inventory with 19 items (13 items for symptom severity, 6
25 items for interference), 0=Nothing, 10=Most severity. Psychometric study has shown that the
26 Chinese version of MDASI has good reliability and validity, so that the Chinese MDASI can be
27 used to measure the severity of multiple symptoms and their impact on function in Chinese cancer
28 patients. Moreover, we have added 5 more items for specific cancer sites in our study to capture
29 special characteristics: constipation is added to all cancers, hot flash and upper limb lymphedema
30 is specific for breast cancer, cough is specific for lung cancer and swallowing difficulty is specific
31 for esophagus cancer. A single “quality of life” item was used to anchor this study.
32
33
34
35
36
37
38
39
40
41
42
43
44

45
46 *Insomnia Severity Index, ISI*
47

48
49 It is a validated scale for measuring insomnia severity in the last two weeks. There are total 7
50 items, 0-4 score for each item, with the sum score of 0-28. 0-7 score indicates no insomnia; 8-14
51 score indicates subclinical insomnia; 15-21 score indicates moderate insomnia, 22-28 score
52 indicates severe insomnia. Simplified Chinese version of ISI has been validated by Lin et al [10].
53
54
55
56
57
58
59

60
Hospital Anxiety and Depression Scale, HADS

1
2
3
4 HADS has 14 items with a score spectrum of 0-4 for each item, which is used to measure the
5
6 anxiety and depression for the patients in the past week. It is used for patients with somatic
7
8 symptoms in the general hospitals with good reliability and validity and recommended for patients
9
10 with advanced cancer or receiving palliative care^[11].
11
12

15 *9 Item Patient Health Questionnaire, PHQ-9*

16
17

18 PHQ-9 is used to evaluate the depression of patients in the past two weeks. The score spectrum of
19
20 symptoms severity is from 0=none at all to 3=almost every day, and the total score was from 0-27.
21
22 Depression can be considered when the sum score is ≥ 10 . Simplified Chinese version of PHQ-9
23
24 has a good validation^[12].
25

26 *EuroQol Five Dimensions questionnaire-5L version, EQ-5D-5L*

27
28

29 EQ-5D-5L is a multidimensional measurement for health-related quality of life, which contains
30
31 these five domain to describe patients' health: 1) mobility; 2) self-care; 3) usual activities; 4)
32
33 pain/discomfort; 5) anxiety/depression, with a scale from 0=No difficulty to 4=extremely
34
35 difficulty^{[13][14]}.
36

37 *Distress Thermometer, DT*

38
39

40 DT is recommended by NCCN in the distress management guideline and was introduced to China
41
42 in 2007. DT has only one item with a scale from 0=No distress to 10=extreme distress. Problem
43
44 list including 5 domains: practical problem, communication problem, emotion problem, physical
45
46 problem, spirit and religion problem. It is recognized as the briefest tool for distress screening,
47
48 especially in busy oncology clinical practice^[15].
49

50
51 The target symptoms are measured by PRO instruments: pain and fatigue are measured by
52
53 MDASI; depression is measured by HADS-D and PHQ-9; anxiety is measured by HADS-A;
54
55 insomnia is measured by ISI and MDASI; nausea and vomiting is measured by MDASI.
56
57
58

59 (2) General demographic and disease data questionnaire.
60

1
2
3
4 General demographic data includes age, sex, occupation, etc. The latter includes disease diagnosis,
5
6 staging, treatment, medication, etc.
7
8

9
10 (3) ECOG score.
11
12

13 This is a health tool that evaluates cancer patient functional status and clinically stratifies these
14
15 patients' ability to tolerate therapies, which runs from 0 to 5, with 0 denoting perfect health and 5
16
17 death [16].
18
19

20
21 (4) Charlson Comorbidity Index.
22
23

24 Comorbid conditions are best evaluated with use of the Charlson Comorbidity Index. Many
25
26 studies have shown that the impact of comorbidities is significant on the survival outcomes and
27
28 prognosis of cancer patients. Here are the conditions used in the comorbidity and the number of
29
30 points they are awarded: score of 1 for myocardial infarction, congestive heart failure, peripheral
31
32 vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease,
33
34 connective tissue disease, peptic ulcer disease, and diabetes mellitus (in terms of diabetes mellitus,
35
36 score of 1 for uncomplicated and 2 for end organ damage); score of 2 for moderate to severe
37
38 chronic kidney disease, hemiplegia, leukemia, malignant lymphoma, solid tumor (2 in case of
39
40 presence and 6 in case tumor is metastatic), liver disease (mild 1 point, moderate to severe 3
41
42 points) and AIDS [17].
43
44
45
46

47 (5) Data collection
48

49 PRO data are collected using an ePRO platform. ePROhub™ is dedicated on ePRO clinical
50
51 research on patient's data collection, assessment and management launched by ePRO Vision
52
53 (Beijing) Health Technology Co Ltd. in 2018. The platform consist of ePROcell™ and
54
55 ePROhub™ two parts. Smartphone-based client, ePROcell™, is for patient's ePRO reporting and
56
57 clinician's ePRO data management, intervention and project management. ePROhub™ platform,
58
59
60

1
2
3
4 the EDC(electronic data capture) complied, is the cloud based symptom, management platform to
5
6 store and assess patient's data, support clinicians manage patient's data and intervention activities
7
8
9 with AI (artificial intelligence) capability, output data to other database platform for further data
10
11 processing. The system could recognize the individual scores of MDASI items due to the cut-point
12
13 that we set-up. For those scale that needed to be calculate for results, such as PHQ-9, were
14
15 captured by WeChat first, save in RedCape and calculate later. Figure 2 (Figure 2: Peking
16
17 University Cancer Hospital project case) shown below gives tot below gives total picture in
18
19 Beijing Cancer Hospital project case.
20
21
22
23

24
25 ePROcell™ is fully integrated with internet-based WeChat, the most popular and the biggest
26
27 social network application in China, to maximize WeChat's advantages of world-class user
28
29 experience and massive population coverage into ePRO practice enable ePRO data collection and
30
31 management happening anywhere and anytime is possible. The pre-register patients can easy click
32
33 the landscape-screen to answer relevant questionnaires and sending back to clinicians via
34
35 cloud-based ePROhub™. Figure 3 shows a screen shot to show how the platform looked to
36
37 patients (Figure 3: The screen of platform looked to patients).The e-informed consent and
38
39 e-signature is implemented before- and after reporting to secure ePRO data effectiveness and
40
41 integrity. The pre-defined threshold of server symptom plus triage process support clinician
42
43 efficiently communicate with patients via ePROcell™ when e-alert and e-reminder occurred.
44
45
46
47
48
49
50
51
52
53

54 According to the pre-defined schedule, ePROcell™ automatically send out reminder message to
55
56 patients during the reporting-day, and confirmation message after patient submit. With
57
58 PRO-calendar and PRO management from ePROcell™, clinicians could easily review and
59
60

1
2
3
4 manage project progress anytime to secure data quality, reporting progress and project quality.
5

6 The ePROcell™ frequently visit patient's and clinical data stored in ePROhub™ and integrated
7
8 backend database platform to support clinicians' regular patient's symptom following up and
9
10 symptom management activities, which is the most efficient way to deliver effective symptom
11
12 intervention and routine care with desired data-driven patient-centered care.
13
14
15

16
17 The cloud-based ePROhub™, located in hospital's datacenter, is the data management platform
18
19 and has dedicated data communication channel with the backend database platform REDCap, the
20
21 US free of Charge SQL database platform, via it's API (Application Program Interface) to
22
23 synchronize pre-defined clinical data, like CRF (case report form) and scale, and patient's ePRO
24
25 data. The ePRO platform could recognize the individual scores of MDASI items due to the
26
27 cut-point that we set-up. For those scale that needed to be calculate for results, such as PHQ-9 are
28
29 captured by WeChat first, saved in REDCap and calculated later. The output data could be
30
31 converted to professional statistics program, like SAS or SPSS, with standard data format for their
32
33 final data analysis. All data are deidentified and stored in the REDCap platform. Data monitoring
34
35 is carried out regularly by the IRB of Peking University Cancer Hospital.
36
37
38
39
40
41
42
43

44 **(6) Semi-structured interview**

45
46
47 A face to face interview, will be conducted following an interview outline but if it is difficult for
48
49 patients to come to the hospital, the interview could be done over the phone.
50
51

52 **Quality control**

53
54
55
56 Investigators received standard operating procedure training before recruiting the patients. A
57
58 standardized operation process manual and an operation video has been made and distributed to all
59
60

1
2
3
4 the research assistant. The Group training was organized for one time while individual
5
6 (one-to-one) training were carried out one-to-one. After the training, all research assistants
7
8
9 required to pass a test of practical operation to getting start on their official work.

10
11 There will be a Question & Answer session to solve operation problems after around 10 cases
12
13 enrolled. In addition, the practical problems that faced by research assistants will be shared in
14
15 WeChat working group at any time.
16
17
18
19
20
21
22
23

24 **Sample size calculation**

25
26 We will use the group-based trajectory model (GBTM) to identify subgroups with distinct
27
28 trajectories of symptom development during the 4 week of investigation. Previous studies showed
29
30 that about 30% of patients with advanced lung cancer reported higher symptom burden than the
31
32 others [18]. The 95% confidence interval according to different symptom prevalence are 40%,
33
34 32.11-47.89%; 30%, 22.62-37.38%; 20%, 13.56-26.44%. To obtain a 95% confidence interval as
35
36 22%-38%, we will need 148 evaluable patients. Considering a 20% attrition, we will recruit 185
37
38 patients.
39
40
41
42
43

44 **Data analysis**

45
46
47 For inclusion in the final analysis, at least the baseline assessment and one successful follow-up is
48
49 required. The last observation carried forward imputation method will be used to impute missing
50
51 data. We will conduct a sensitivity analysis to exam whether the symptom burden of the complete
52
53 cases is significantly different from that of cases with missing data.
54
55
56
57
58
59
60

1
2
3
4 Continuous data will be described as mean \pm SD while categorical data will be described as
5
6 number and percentage. The changing trends of target symptoms intensity over time will be
7
8 presented by line charts. The improvement on the intensity of the patients' target symptoms and
9
10 the PRO impact of target symptoms on patient's life in 4 weeks after the initial visiting will be
11
12 analyzed by general linear mixed model, while the appropriate frequency of ePRO screening for
13
14 different symptoms will be determined according to significant change point of ePRO score. The
15
16 impact of target symptoms intensity on quality of life, the alert value of each symptom and, most
17
18 appropriate PRO items for the targeted symptoms of the screening and the effects of co-morbidity
19
20 and chronic diseases on symptom burden and symptom management will be analyzed by
21
22 regression models. Differences are considered statistically significant if the two-tailed p values of
23
24
25
26
27
28
29
30 <0.05.
31
32

33 The recoded qualitative materials will be transcribed into words and be analyzed using a thematic
34
35 analysis to develop a frame work of topics on causes of uncontrolled symptoms. All quantitative
36
37 data analysis will be performed using R 3.6.1 and Python 3.7.4, while the transcription of
38
39 qualitative interview will be coded and analyzed using NVivo 11.0.
40
41
42
43
44
45
46
47

48 **DISCUSSION**

49
50 Advanced cancer patients suffered from severe symptom burden and ePRO platform could be a
51
52 useful tool to monitor and to manage the patients' symptoms at home and it is urgent to
53
54 incorporate ePRO into patients' electronic health record ^[19]. This is a feasibility study to
55
56
57
58
59
60

1
2
3
4 investigate the use of an electronic patient-reported outcome platform, and this data will provide
5
6 guide to apply this novel platform in clinical practice of symptom management.
7
8

9
10 The patients who visit symptom management clinic at the first time usually suffered one or more
11
12 kinds of severe symptoms and will be given drug-therapy or non-drug therapy or both to address
13
14 their symptoms. Usually in the first few days after their first visit, the symptoms will change
15
16 rapidly. So we arrange 7 follow-up on Day 1, Day 3, Day 7, Day 10, Day 14, Day 21 and Day 28
17
18 after the first visit.
19
20
21
22

23 The information security is very important. Information of completion progress would be shown
24
25 on the physician sites. Each response on WeChat requires an authorized security token to be
26
27 submitted, a secure network connection ensures that collected responses were only sent to the
28
29 database established in Beijing Cancer Hospital. The ePRO and data transmission network were
30
31 reviewed and approved by the information security engineer of Beijing Cancer Hospital.
32
33
34
35

36
37 So far this ePRO platform hasn't been investigated into patient records and the ePRO platform
38
39 will send a notification to remind the patients who get worsen symptoms to visit the symptom
40
41 management clinic as soon as possible. It is urgent to incorporate ePRO into patients' electronic
42
43 health record. ePRO platform could be a useful tool to monitor and manage the patients'
44
45 symptoms at home.
46
47
48
49

50
51 If the results of this study show this platform is feasible to use and is acceptable by the patients,
52
53 our next goal is to implement ePRO into clinical practice by integrate it with patient's electronic
54
55 health record. We hope this platform could be helpful for clinicians to capture their patients'
56
57
58
59
60

1
2
3
4 symptom change in-time and offer a more flexible symptom/ medication management when
5
6
7 worsening symptoms were developed.
8
9

10 Although there are culture differences between Chinese and Western culture, the intervention that
11
12 this study describes could be replicated in many countries allowing for the use of alternative
13
14
15 mobile platforms, and the results would be widely applicable.
16
17
18
19
20

21 **Patient and public involvement**

22
23
24 Patients and the general public were not involved in the design, recruitment and implementation of
25
26
27 the study. We have no plans of informing the study participants regarding the results of this study.
28
29
30 However, the results will be disseminated to the applicants in the form of a published article as
31
32
33 requested.
34
35
36
37
38

39 **ETHICS AND DISSEMINATION**

40
41
42 The protocol is registered and any amendments to the research protocol will be submitted for IRB
43
44
45 approval. The results in this study will be first reported at relevant academic conferences,
46
47
48 workshops and then will eventually be published in peer-reviewed journals.
49
50
51
52

53 **Author Affiliations**

54
55
56 ¹ Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Key laboratory
57
58 of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
59
60

1
2
3
4 ² School of Public Health and Management, Chongqing Medical University, Chongqing, China.
5
6
7

8 **Contributors** LT, YP, YH and QS contributed to the study design. LT, YP, YH, XH, ZL, CZ,
9
10 YZ, SH, YW, YZ, LS, BW, XL performed the study. YP, YH, XH, ZL, CZ drafted the initial
11
12 manuscript. LT and QS revised the draft. All authors have reviewed and approved the final
13
14 manuscript.
15

16
17
18 **Funding** This research received no specific grant from any funding agency in the public,
19
20 commercial or not-for-profit sectors
21
22

23
24
25 **Competing interests** None declared.
26

27 Patient consent for publication Not required.
28
29

30
31 **Ethics approval** This study was approved by the (IRB) of Peking University Cancer Hospital on
32
33 14 May 2019 (2019YJZ34).
34
35

36 **ORCID ID**
37

38 Lili Tang <https://orcid.org/0000-0003-1524-4617>
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- [1] Chen W , Zheng R , Baade P D , et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
- [2] Reilly C M, Deborah Watkins Bruner, Sandra A. Mitchell, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment [J]. Supportive Care in Cancer, 2013, 21(6):1525-1550.
- [3] Dantzer, Robert, Meagher, Mary W, Cleeland, Charles S. Translational approaches to treatment-induced symptoms in cancer patients[J]. Nature Reviews Clinical Oncology, 9(7):414-426.
- [4] Henry D H , Viswanathan H N , Elkin E P , et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.[J]. Supportive Care in Cancer, 2008, 16(7):791-801.
- [5] Cleeland, C S, Fengmin Zhao, Victor T. Chang, et al., The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer, 2013. 119(24): p. 4333-40.
- [6] Basch, E, Deal A M, Dueck A C, et al., Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA, 2017. 318(2):197-198.

- 1
2
3
4 [7] Denis F , Basch E , Septans A L , et al. Two-Year Survival Comparing Web-Based Symptom
5
6 Monitoring vs Routine Surveillance Following Treatment for Lung Cancer[J]. JAMA, 2019,
7
8 321(3):306-307.
9
10
11
12 [8] Cleeland C S , Mendoza T R , Wang X S , et al. Assessing symptom distress in cancer
13
14 patients : The M. D. Anderson Symptom Inventory. Cancer, 2000, 89(7):1634-1646.
15
16
17
18 [9] Xin, Shelley, Wang, et al. Chinese version of the M. D. Anderson Symptom Inventory :
19
20 Validation and application of symptom measurement in cancer patients[J]. Cancer, 2004.
21
22
23
24 [10] Lin R M , Xie S S , Yan W J , et al. Factor structure and psychometric properties of the
25
26 Insomnia Severity Index in Mainland China. Social Behavior and Personality: an international
27
28 journal, 2018, 46(2).
29
30
31
32 [11] Guo Hua Z , Ming Zhi X U . Factorial Structure of the Hospital Anxiety and Depression
33
34 Scale in Outpatients with Somatic Disease. Chinese Journal of Clinical Psychology. 2006,
35
36 14(6):591-592.
37
38
39
40
41 [12] Chen S , Fang Y , Psych H C F , et al. Validation of the nine-item Patient Health
42
43 Questionnaire to screen for major depression in a Chinese primary care population. Asia Pac
44
45 Psychiatry. 2013,5(2):61-68.
46
47
48
49 [13] Luo N , Liu G , Li M , et al. Estimating an EQ-5D-5L Value Set for China. Value in Health,
50
51 2017, 20(4):662-669.
52
53
54
55 [14] Liu L , Li S , Wang M , et al. Comparison of EQ-5D-5L health state utilities using four
56
57 country-specific tariffs on a breast cancer patient sample in mainland China. Patient Preference &
58
59
60

1
2
3
4 Adherence, 2017, 11:1049-1056.].

5
6
7 [15] Tang L, Zhang Y, Pang Y, et al. Validation and Reliability of Distress Thermometer in
8
9 Chinese Cancer Patients. *Chin J Cancer Res.* 2011,23(1):54-58.

10
11
12 [16] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP.
13
14 Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.*
15
16 1982;5(6):649-55.

17
18
19 [17] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
20
21 comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;
22
23 40(5):373-83.

24
25
26 [18] Cleeland CS et al. Levels of symptom burden during chemotherapy for advanced lung cancer:
27
28 differences between public hospitals and a tertiary cancer center. *J Clin Oncol.* 2011 Jul
29
30 20;29(21):2859-65.

31
32
33 [19] Marandino L, Necchi A, Aglietta M, Di Maio M. COVID-19 Emergency and the Need to
34
35 Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. *JCO*
36
37 *Oncol Pract.* 2020 May 1:OP2000237. doi: 10.1200/OP.20.00237


38
39
40
41
42
43
44
45
46
47
48
49
50 Figure 1: The flow chart of this study

51
52
53 Figure 2: Peking University Cancer Hospital project case

54
55
56
57 Figure 3: The screen of platform looked to patients
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



42 Figure 1 The flow chart of this study

43 90x99mm (300 x 300 DPI)


44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Peking University Cancer Hospital project case
160x59mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



The screen of platform looked to patients

315x207mm (96 x 96 DPI)

BMJ Open

A longitudinal study of symptom burden in outpatients with advanced cancers based on Electronic Patient Reported Outcome (ePRO) platform: a single institution, prospective study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038223.R2
Article Type:	Protocol
Date Submitted by the Author:	18-Sep-2020
Complete List of Authors:	Tang, Lili; Peking University Cancer Hospital, Department of Psycho-Oncology Pang, Ying; Peking University Cancer Hospital, Department of Psycho-Oncology He, Yi; Peking University Cancer Hospital, Department of Psycho-Oncology Shi, Qiuling; Chongqing Medical University, School of Public Health and Management Han, Xinkun; Peking University Cancer Hospital, Department of Psycho-Oncology Li, Zimeng; Peking University Cancer Hospital, Department of Psycho-Oncology Zhou, Chengcheng; Peking University Cancer Hospital, Department of Psycho-Oncology Zhou, Yuhe; Peking University Cancer Hospital, Department of Psycho-Oncology He, Shuangzhi; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Yan; Peking University Cancer Hospital, Department of Psycho-Oncology Zhang, Yening; Peking University Cancer Hospital, Department of Psycho-Oncology Song, Lili; Peking University Cancer Hospital, Department of Psycho-Oncology Wang, Bingmei; Peking University Cancer Hospital, Department of Psycho-Oncology Li, Xiumin; Peking University Cancer Hospital, Department of Psycho-Oncology
Primary Subject Heading:	Palliative care
Secondary Subject Heading:	Oncology
Keywords:	Adult palliative care < PALLIATIVE CARE, Adult oncology < ONCOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A longitudinal study of symptom burden in outpatients with advanced cancers based**
4 **on Electronic Patient Reported Outcome (ePRO) platform: a single institution,**
5 **prospective study protocol**
6
7

8 Lili Tang^{1, *}, Ying Pang¹, Yi He¹, Qiuling Shi², Xinkun Han¹, Zimeng Li¹, Chengcheng
9 Zhou¹, Yuhe Zhou¹, Shuangzhi He¹, Yan Wang¹, Yening Zhang¹, Lili Song¹, Bingmei
10 Wang¹, Xiumin Li¹
11
12
13
14

15 **Author Affiliations**
16

17
18 ¹Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Key
19 laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing,
20 China.
21
22

23
24 ² School of Public Health and Management, Chongqing Medical University, Chongqing,
25 China.
26
27
28
29
30
31
32

33 * Corresponding author: Department of Psycho-oncology, Peking University Cancer Hospital
34 & Institute, Key laboratory of Carcinogenesis and Translational Research (Ministry of
35 Education), 52 Fucheng Road, Beijing, 100142, China. Fax: +86 10 88196648.
36
37
38

39 E-mail addresses: tanglili_cpos@126.com (LiLi Tang)
40
41
42
43

44 The first two authors contributed equally to this manuscript.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: An electronic Patient Report Outcome (ePRO) platform is needed for implementing evidence-based symptom management in outpatients with advanced cancer. We describe the overall protocol and the methodology for measuring symptom burden, to provide critical parameters needed to implement symptom management on the ePRO platform.

Methods and analysis: The study focuses on patients with advanced lung cancer, stomach cancer, esophagus cancer, liver cancer, colorectal cancer or breast cancer. The primary outcome is the change of symptom burden. MD Anderson Symptom Inventory (MDASI), and other PRO instruments (ISI, HADS, PHQ-9, and EQ5D5L) were used. The secondary outcomes include feasibility of using ePRO, symptom related QoL, reasons for no improvement of symptoms, defining frequency of PRO assessments and cut-points, items for screening, and management of comorbidity and satisfaction with ePRO platform in patients and health providers. After initial outpatient visit for baseline assessment, ePRO system will automatically send follow-up notification 7 times over 4 weeks to patients. The characteristics and changing trajectory of symptoms of patients will be described. Parameters for using PROs, such as optimal time points for follow-up and cut-off point for alert will be determined. The feasibility of ePRO platform to track the changes of target symptoms in outpatients will be evaluated.

Ethics and dissemination: The study protocol and related documents were approved by the Institutional Research Board (IRB) of Peking University Cancer Hospital on 14 May, 2019

(2019YJZ34). The results of this study will be disseminated through academic workshops, peer-reviewed publications and conferences.

Trial Registration: chictr.org.cn ChiCTR1900023560

Key words: advanced cancer, symptom management, out-patients, Electronic Patient Reported Outcome, a longitudinal study

There are several strengths and limitations of this study.

- The study is a prospective cohort study with a total of 7 follow-ups conducted within 4 weeks. It focuses on establishing a symptom management platform for outpatient ePRO and obtain the dynamic symptoms trajectory of patients outside the hospital
- Instead of a single tumor site, the six most common tumor sites are represented: lung cancer, gastric cancer, esophageal cancer, liver cancer, colorectal cancer, breast cancer.
- PRO data are collected using an e-questionnaire based on WeChat, a major communication app in China.
- A group of questionnaires are used to measure the comprehensive well-being of patients, mainly including MDASI-C, ISI, HADS, PHQ-9 and EQ5D5L.

INTRODUCTION

According to the official report by the National Central Cancer Registry of China, cancer is the leading cause of death in China; there were 4.3 million newly diagnosed cancer cases and 2.8 million cancer deaths in 2015 in China. Lung cancer, gastric cancer, liver cancer,

1
2
3
4 esophageal cancer and colorectal cancer rank as the top five cancers in men, and breast
5
6 cancer, lung cancer, gastric cancer, colorectal cancer and esophageal cancer rank as the top
7
8 five cancers in women^[1]. Cancer patients suffer from various symptoms due to the disease
9
10 itself and treatment-related adverse reactions ^[2-4]. Studies have shown that one third of
11
12 patients undergoing cancer treatments reported three or more moderate to severe symptoms
13
14 ^[5]. The symptom burden of advanced cancer patients is even more serious.^[4, 5]If the symptoms
15
16 are not addressed properly in time, the quality of life and daily functions will be affected
17
18 negatively and even shorten the survival period of patients.
19
20
21
22
23
24

25 In recent years, several studies have shown that good symptom management based on
26
27 patient-reported outcome (PRO) can benefit advanced cancer patients. For example, a
28
29 single-centered study published in JAMA in 2017 showed that systematic symptom
30
31 monitoring can significantly prolong the survival of patients by 5.2 months ^[6], which even
32
33 achieved better results than most newly approved anti-cancer drugs in 2016. In 2019, a
34
35 multi-centered study of Web-based follow-up of PRO symptoms demonstrated once again
36
37 that this approach could bring survival benefits to patients.^[7]
38
39
40
41
42
43

44 However, there are few studies on effective symptom management of the cancer patients in
45
46 routine patient care in China. The clinical doctors and nurses need a help for how to quickly
47
48 capture the patient's dynamic change on symptom burden in patient's routine clinic
49
50 appointment under the busy work flow, and the patients also need an approach for reporting
51
52 symptoms actively. A lot of the symptom management are dealt with in the outpatient clinic,
53
54 however, there is no monitoring system on patients' status when they are out of the hospital.
55
56
57
58
59
60

1
2
3
4 In order to resolve this problem, we have established an ePRO platform to monitor the
5
6 symptom changes when the patients have left the clinic and gone back home. The plat form is
7
8 designed to monitor the changes of the symptom burden through PROs among outpatients.
9
10 With lack of longitudinal data of physical, psychological, social symptom burden for Chinese
11
12 oncology patients, the proposed study aimed to include PROs of multiple symptom
13
14 assessment tool, functioning measure and HRQoL measure. Since there are many differences
15
16 between the Chinese culture and Western culture, the ePRO platform is also in different
17
18 format. In Western countries, some of the electronic applications are through e-mail, but
19
20 e-mail is not widely used in Chinese population especially by the elderly. We inserted the
21
22 ePRO platform in the Wechat applet in mobile, for Wechat is the most popular social
23
24 networking app in China. According to the latest report, there are 1.15 billion monthly active
25
26 user of WeChat, over 80% population in China^[8]. And according to our experiences, most of
27
28 our patients, even the elderly can use Wechat.
29
30
31
32
33
34
35
36
37
38
39
40

41 **METHODS AND ANALYSIS**

42 **Study design**

43
44
45 This is a real-world, ongoing, longitudinal single-center prospective study with a total of 7
46
47 follow-ups conducted within 4 weeks after the first visit of the symptom management
48
49 clinic(on Day 1, Day 3, Day 7, Day 10, Day 14, Day 21 and Day 28). The flow chart of this
50
51 study is shown in Figure 1 (Figure 1: The flow chart of this study). After the last follow-up, a
52
53
54
55
56
57
58
59
60

1
2
3
4 semi-structured interview will be conducted with patients whose symptom scores worsen or
5
6 not improved after 4 weeks.
7
8
9

10 11 12 **Setting**

13
14
15 This study was initiated by Department of Psycho-oncology In Peking University Cancer
16
17 Hospital and the study was started in June 1st, 2019 and was planned to be finished by
18
19 December 31, 2020. However, the completion data may be delayed for a few months because
20
21 of the COVID-19. The site is the symptom management outpatient clinic in Peking University
22
23 Cancer Hospital.
24
25
26
27
28
29
30
31

32 **Study population and eligibility criteria and recruitment**

33
34
35 Patients who visit the symptom management clinic for managing difficult pain or
36
37 psychological symptoms. Most of the patients are referred by their oncologist, some patients
38
39 were referred by other patients who had been treated in this clinic, while some patients saw
40
41 advertisements. Those patients include both patients undergoing active treatment for cancer
42
43 and patients receiving palliative symptomatic management. Eligible patients are required to
44
45 be 1) Over 18 years of age; 2) fluent in Chinese; 3) a confirmed diagnosis of advanced lung
46
47 cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer and breast cancer.;4)
48
49 ability to give consent. Exclusion criteria include 1) a history of major severe mental
50
51 disorders, unable to cooperate with the investigator; 2) poor physical or mental condition,
52
53
54
55
56
57
58
59
60

1
2
3
4 judged by the attending physician, not able to complete the whole study; 3) being not able to
5
6 use ePRO platform.
7
8

9
10 All eligible patients who visit the symptom management clinic at the first time will be invited
11
12 to participate in this study by the doctors in this clinic. If the patients are interested in this
13
14 study, a research assistant will inform patients in detail and get their written informed
15
16 consent.
17
18

19 20 21 **Study objectives and outcomes** 22

23
24 The primary objective is systemic monitoring changes of the intensity of target symptoms
25
26 (including pain, fatigue, insomnia, anxiety, depression, nausea and vomiting) in patients with
27
28 advanced cancer in the symptom management clinic of Peking University cancer hospital
29
30 during a systematic follow-up within 4 weeks.
31
32

33
34
35 The second objectives are as follow:
36
37

38 (1) Evaluating the feasibility of tracking changes in target symptoms in outpatients through
39
40 the ePRO follow-up system.
41
42

43
44 1) At least 50% of patients completed self-report within 24 hours after being sent the
45
46 follow-up message; more than 70% of patients completed self-report within 24 hours
47
48 after being called; at least 70% of patients complete all self-reports within 4 weeks.
49
50

51
52 2) The percentage of patients who met the eligibility criteria agreed to participate in the
53
54 study is 80%.
55

56 (2) Observing the changes of quality of life in patients seeking symptom management in
57
58 Department of Psycho-Oncology within 4 weeks after initial visiting.
59
60

- (3) Finding out the reasons why the symptoms of outpatients cannot be improved within 4 weeks after the first visiting through a qualitative research.(interview)
- (4) Determining the appropriate frequency of PRO symptom screening through the description and analysis of the changes in patients' symptoms during the 4-week follow-up after initial visiting.
- (5) Exploring the most appropriate PRO items for the targeted symptoms of the screening.
- (6) Determining the alert score of each PRO symptom through the analysis of the symptom changes during the follow-up 4 weeks after initial visiting.
- (7) Analyzing the effects of co-morbidity and chronic diseases on symptom burden and symptom management of cancer patients.
- (8) To explore the satisfaction with ePRO platform in patients and health provider by a focus group interview.

Withdrawal criteria

Patients undergo a brief interview with a research assistant to identify the following exclusion criteria: (1) major communication difficulties; (2) inability to commit to the required 7 follow-up PRO (i.e., too ill to participate); (3) cognitive impairment;(4) those who do not follow the study protocol (deliberately providing incorrect PRO data) ;(5) those who ask to withdraw from the research or (6) other conditions that require withdrawal as assessed by the investigator

1
2
3
4 Study instruments, Data collection, management and monitoring, qualitative interview
5
6

7 Totally 9 study instruments are used in this study, including 6 PRO instruments. The patients
8
9
10 need to fill all the questionnaires only for three times at the baseline assessment, Day 14 and Day
11
12 28 follow-up. At other follow-ups, patients only need to fill MD Anderson Symptom Inventory
13
14
15 with only 19 items.
16

17
18 (1) PRO instruments
19

20
21 *MD Anderson Symptom Inventory, MDASI.*
22

23
24 MDASI ^{[9][10]} is a widely used symptom inventory with 19 items (13 items for symptom
25
26 severity, 6 items for interference), 0=Nothing, 10=Most severity. Psychometric study has
27
28 shown that the Chinese version of MDASI has good reliability and validity, so that the
29
30 Chinese MDASI can be used to measure the severity of multiple symptoms and their impact
31
32 on function in Chinese cancer patients. Moreover, we have added 5 more items for specific
33
34 cancer sites in our study to capture special characteristics: hot flash and upper limb
35
36 lymphedema is specific for breast cancer; cough is specific for lung cancer and
37
38 swallowing difficulty is specific for esophagus cancer; constipation is added to all cancers,
39
40 because pain is one of the most common symptoms in advanced cancer patients in all types of
41
42 cancer and the proportion of these patients using opioid is high. Constipation is one of the
43
44 most common side effects using opioid, so we added constipation to all cancers. Additionally
45
46 a single “quality of life” item was used to anchor this study.
47
48
49
50
51
52
53

54
55
56 *Insomnia Severity Index, ISI*
57

58
59 It is a validated scale for measuring insomnia severity in the last two weeks. There are total 7
60

1
2
3
4 items, 0-4 score for each item, with the sum score of 0-28.0-7 score indicates no insomnia;
5
6 8-14 score indicates subclinical insomnia; 15-21 score indicates moderate insomnia, 22-28
7
8 score indicates severe insomnia. Simplified Chinese version of ISI has been validated by Lin
9
10 et al ^[11].

11 12 13 14 15 *Hospital Anxiety and Depression Scale, HADS*

16
17
18 HADS has 14 items with a score spectrum of 0-4 for each item, which is used to measure the
19
20 anxiety and depression for the patients in the past week. It is used for patients with somatic
21
22 symptoms in the general hospitals with good reliability and validity and recommended for
23
24 patients with advanced cancer or receiving palliative care ^[12].

25 26 27 28 29 *9 Item Patient Health Questionnaire, PHQ-9*

30
31
32 PHQ-9 is used to evaluate the depression of patients in the past two weeks. The score
33
34 spectrum of symptoms severity is from 0=none at all to 3=almost every day, and the total
35
36 score was from 0-27. Depression can be considered when the sum score is ≥ 10 . Simplified
37
38 Chinese version of PHQ-9 has a good validation ^[13].

39 40 41 *EuroQol Five Dimensions questionnaire-5L version, EQ-5D-5L*

42
43 EQ-5D-5L is a multidimensional measurement for health-related quality of life, which
44
45 contains these five domain to describe patients' health: 1) mobility; 2) self-care; 3) usual
46
47 activities; 4) pain/discomfort; 5) anxiety/depression, with a scale from 0=No difficulty to
48
49 4=extremely difficulty^{[14][15]}

50 51 52 *Distress Thermometer, DT*

53
54 DT is recommended by NCCN in the distress management guideline and was introduced to
55
56 China in 2007. DT has only one item with a scale from 0=No distress to 10=extreme distress.
57
58 Problem list including 5 domains: practical problem, communication problem, emotion
59
60

1
2
3
4 problem, physical problem, spirit and religion problem. It is recognized as the briefest tool for
5 distress screening, especially in busy oncology clinical practice ^[16].
6
7

8 The target symptoms are measured by PRO instruments: pain and fatigue are measured by
9 MDASI; depression is measured by HADS-D and PHQ-9; anxiety is measured by HADS-A;
10
11
12
13
14 insomnia is measured by ISI and MDASI; nausea and vomiting is measured by MDASI.
15

16 17 (2) General demographic and disease data questionnaire.

18
19
20 General demographic data includes age, sex, occupation, etc. The latter includes disease
21
22
23 diagnosis, staging, treatment, medication, etc.
24

25 26 (3) ECOG score.

27
28
29 This is a health tool that evaluates cancer patient functional status and clinically stratifies
30
31
32 these patients' ability to tolerate therapies, which runs from 0 to 5, with 0 denoting perfect
33
34 health and 5 death ^[17]. This measure is done by doctors.
35

36 37 (4) Charlson Comorbidity Index.

38
39
40 Comorbid conditions are best evaluated with use of the Charlson Comorbidity Index. Many
41
42 studies have shown that the impact of comorbidities is significant on the survival outcomes
43
44 and prognosis of cancer patients. Here are the conditions used in the comorbidity and the
45
46 number of points they are awarded: score of 1 for myocardial infarction, congestive heart
47
48 failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive
49
50 pulmonary disease, connective tissue disease, peptic ulcer disease, and diabetes mellitus (in
51
52 terms of diabetes mellitus, score of 1 for uncomplicated and 2 for end organ damage); score
53
54 of 2 for moderate to severe chronic kidney disease, hemiplegia, leukemia, malignant
55
56 lymphoma, solid tumor (2 in case of presence and 6 in case tumor is metastatic), liver
57
58 disease (mild 1 point, moderate to severe 3 points) and AIDS ^[18]. It is determined by chart
59
60 review.

1
2
3
4
5
6 (5) Data collection
7

8 PRO data are collected using an ePRO platform. ePROhub™ is dedicated on ePRO clinical
9 research on patient's data collection, assessment and management launched by ePRO Vision
10
11 (Beijing) Health Technology Co Ltd. in 2018. The platform consist of ePROcell™ and
12
13 ePROhub™ two parts. Smartphone-based client, ePROcell™, is for patient's ePRO reporting
14
15 and clinician's ePRO data management, intervention and project management. ePROhub™
16
17 platform, the EDC(electronic data capture) complied, is the cloud based symptom,
18
19 management platform to store and assess patient's data, support clinicians manage patient's
20
21 data and intervention activities with AI (artificial intelligence) capability, output data to other
22
23 database platform for further data processing. The system could recognize the individual
24
25 scores of MDASI items due to the cut-point that we set-up. For those scale that needed to be
26
27 calculate for results, such as PHQ-9, were captured by WeChat first, save in RedCap and
28
29 calculate later. Figure 2 (Figure 2: Peking University Cancer Hospital project case) shown
30
31 below gives tot below gives total picture in Beijing Cancer Hospital project case.
32
33
34
35
36
37
38
39
40
41

42
43 ePROcell™ is fully integrated with internet-based WeChat, the most popular and the biggest
44
45 social network application in China, to maximize WeChat's advantages of world-class user
46
47 experience and massive population coverage into ePRO practice enable ePRO data collection
48
49 and management happening anywhere and anytime is possible. The pre-register patients can
50
51 easy click the landscape-screen to answer relevant questionnaires and sending back to
52
53 clinicians via cloud-based ePROhub™. Figure 3 shows a screen shot to show how the
54
55 platform looks to patients (Figure 3: The screen of platform looked to patients).The
56
57
58
59
60

1
2
3
4 e-informed consent and e-signature is implemented before- and after reporting to secure
5
6 ePRO data effectiveness and integrity. The pre-defined threshold of server symptom plus
7
8 triage process support clinician efficiently communicate with patients via ePROcell™ when
9
10 e-alert and e-reminder occurred.
11
12
13

14
15
16
17 According to the pre-defined schedule, ePROcell™ automatically send out reminder message
18
19 to patients during the reporting-day, and confirmation message after patient submit. With
20
21 PRO-calendar and PRO management from ePROcell™, clinicians could easily review and
22
23 manage project progress anytime to secure data quality, reporting progress and project
24
25 quality. The ePROcell™ frequently visit patient's and clinical data stored in ePROhub™
26
27 and integrated backend database platform to support clinicians' regular patient's symptom
28
29 following up and symptom management activities, which is the most efficient way to deliver
30
31 effective symptom intervention and routine care with desired data-driven patient-centered
32
33 care.
34
35
36
37
38
39
40

41 The cloud-based ePROhub™, located in hospital's datacenter, is the data management
42
43 platform and has dedicated data communication channel with the backend database platform
44
45 REDCap, the US free of Charge SQL database platform, via it's API (Application Program
46
47 Interface) to synchronize pre-defined clinical data, like CRF (case report form) and scale, and
48
49 patient's ePRO data. The ePRO platform can recognize the individual scores of MDASI items
50
51 due to the cut-point that we set-up. For those scale that needed to be calculate for results, such
52
53 as PHQ-9 are captured by WeChat first, saved in REDCap and calculated later. The output
54
55 data could be converted to professional statistics program, like SAS or SPSS, with standard
56
57
58
59
60

1
2
3
4 data format for their final data analysis. All data are DE identified and stored in the REDCap
5
6 platform. Protocol monitoring is carried out regularly by the IRB of Peking University Cancer
7
8 Hospital.
9

10 11 12 **(6) Semi-structured interview** 13

14
15 To explore the reasons for why some symptoms could not be improved within 4 weeks after the
16
17 first visiting. A semi-structured interview will be done in patients with any symptom severity
18
19 item score of MDASI increased or decreased less than 2 points. The guide of interview was
20
21 developed with stockholder among our mean problem: why some symptoms could not be
22
23 improved within 4 weeks after the first visiting. Stockholders include physicians and nurses in
24
25 symptom management clinic, patients and caregivers. A face to face interview, will be
26
27 conducted following an interview outline but if it is difficult for patients to come to the
28
29 hospital, the interview will be done over the phone.
30
31
32
33
34
35
36

37 The recoded qualitative materials will be transcribed into words and be analyzed using a
38
39 thematic analysis to develop a frame work of topics on causes of uncontrolled symptoms. All
40
41 quantitative data analysis will be performed using R 3.6.1 and Python 3.7.4, while the
42
43 transcription of qualitative interview will be coded and analyzed using NVivo 11.0.
44
45
46
47
48
49
50

51 **Quality control** 52

53
54 Investigators received standard operating procedure training before recruiting the patients. A
55
56 standardized operation process manual and an operation video has been made and distributed
57
58 to all the research assistant. The Group training was organized for one time while individual
59
60

1
2
3
4 (one-to-one) training were carried out one-to-one. After the training, all research assistants
5
6 required to pass a test of practical operation to getting start on their official work.
7

8
9 There will be a Question& Answer session to solve operation problems after around 10 cases
10
11 enrolled. In addition, the practical problems that faced by research assistants will be shared in
12
13 WeChat working group at any time.
14
15

16 17 18 19 20 **Sample size calculation** 21

22
23 We will use the group-based trajectory model (GBTM) to identify subgroups with distinct
24
25 trajectories of symptom development during the 4 week of investigation. Previous studies
26
27 showed that about 30% of patients with advanced lung cancer reported higher symptom
28
29 burden than the others^[19]. To obtain a 95% confidence interval for 30%, we will need 148
30
31 evaluable patients, which was according to different symptom prevalence for 40%,
32
33 32.11-47.89%; 30%, 22.62-37.38%; 20%, 13.56-26.44%. Considering a 20% attrition, we
34
35 will recruit 185 patients.
36
37
38
39
40
41
42
43
44

45 **Data analysis** 46

47
48 For inclusion in the final analysis, at least the baseline assessment and one successful
49
50 follow-up is required. The last observation carried forward imputation method will be used to
51
52 impute missing data. We will conduct a sensitivity analysis to examine whether the symptom
53
54 burden of the complete cases is significantly different from that of cases with missing data.
55
56
57
58
59
60

1
2
3
4 Continuous data will be described as mean \pm SD while categorical data will be described as
5
6 number and percentage. The changing trends of target symptoms intensity over time will be
7
8 presented by line charts. The improvement on the intensity of the patients' target symptoms
9
10 and the PRO impact of target symptoms on patient's life in 4 weeks after the initial visiting
11
12 will be analyzed by general linear mixed model, while the appropriate frequency of ePRO
13
14 screening for different symptoms will be determined according to significant change point of
15
16 ePRO score. The impact of target symptoms intensity on quality of life, the alert value of each
17
18 symptom and, most appropriate PRO items for the targeted symptoms of the screening and
19
20 the effects of co-morbidity and chronic diseases on symptom burden and symptom
21
22 management will be analyzed by regression models. Differences are considered statistically
23
24 significant if the two-tailed p values of <0.05 .
25
26
27
28
29
30
31
32

33 **Patient and public involvement**

34
35
36 Patients and the general public were not involved in the design, recruitment and
37
38 implementation of the study except development of the semi-interview guide. We have no
39
40 plans of informing the study participants regarding the results of this study. However, the
41
42 results will be disseminated to the applicants in the form of a published article as requested.
43
44
45
46
47
48
49

50 **ETHICS AND DISSEMINATION**

51
52
53
54 The protocol was approved by the IRB of Peking University Cancer Hospital on 14 May 2019
55
56 (2019YJZ34) and any amendments to the research protocol will be submitted for IRB
57
58
59
60

1
2
3
4 approval. The results in this study will be first reported at relevant academic conferences,
5
6 workshops and then will eventually be published in peer-reviewed journals.
7
8
9

10 11 12 13 **DISCUSSION**

14
15
16 Advanced cancer patients suffered from severe symptom burden and ePRO platform could be
17
18 a useful tool to monitor and to manage the patients' symptoms at home and it is urgent to
19
20 incorporate ePRO into patients' electronic health record [20]. This is a feasibility study to
21
22 investigate the use of an electronic patient-reported outcome platform, and this data will
23
24 provide guide to apply this novel platform in clinical practice of symptom management.
25
26
27

28
29
30 The patients who visit symptom management clinic at the first time usually suffer from one or
31
32 more severe symptoms and will be given drug-therapy or non-drug therapy or both to address
33
34 their symptoms. Usually in the first few days after their first visit, the symptoms will change
35
36 rapidly. So we arrange 7 follow-up on Day 1, Day 3, Day 7, Day 10, Day 14, Day 21 and Day
37
38 28 after the first visit.
39
40
41

42
43
44 The information privacy is very important. Information of completion progress would be
45
46 shown on the physician sites. Each response on WeChat requires an authorized security token
47
48 to be submitted, a secure network connection ensures that collected responses were only sent
49
50 to the database established in Beijing Cancer Hospital. The ePRO and data transmission
51
52 network were reviewed and approved by the information security engineer of Beijing Cancer
53
54 Hospital.
55
56
57
58
59
60

1
2
3
4 So far this ePRO platform hasn't been investigated into patient records and the ePRO
5
6 platform will send a notification to remind the patients with worsening symptoms to visit the
7
8 symptom management clinic as soon as possible. It is urgent to incorporate ePRO into
9
10 patients' electronic health record. ePRO platform could be a useful tool to monitor and
11
12 manage the patients' symptoms at home.
13
14
15

16
17 If the results of this study show this platform is feasible to use and is accepted by the patients
18
19 and staff, our next goal is to implement ePRO into clinical practice by integrate the ePRO
20
21 with patient's electronic health record. We hope this platform could be helpful for clinicians
22
23 to capture their patients' symptom change in-time and offer a more flexible symptom/
24
25 medication management when worsening symptoms develop.
26
27
28
29

30
31 Although there are culture differences between Chinese and Western culture, the intervention
32
33 that this study describes could be replicated in many countries allowing for the use of
34
35 alternative mobile platforms, and the results would be widely applicable.
36
37
38
39

40
41
42
43
44 **Contributors** LT, YP, YH and QS contributed to the study design. LT, YP, YH, XH, ZL, CZ,
45
46 YZ, SH, YW, YZ, LS, BW, XL performed the study. YP, YH, XH, ZL, CZ drafted the initial
47
48 manuscript. LT and QS revised the draft. All authors have reviewed and approved the final
49
50 manuscript.
51

52
53
54
55 **Funding** This research received no specific grant from any funding agency in the public,
56
57 commercial or not-for-profit sectors
58
59
60

1
2
3 **Competing interests** None declared.
4

5 Patient consent for publication Not required.
6
7
8
9

10 **ORCID ID**
11

12 Lili Tang <https://orcid.org/0000-0003-1524-4617>
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

- [1] Chen W , Zheng R , Baade P D , et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
- [2] Reilly C M, Deborah Watkins Bruner, Sandra A. Mitchell, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment[J]. Supportive Care in Cancer, 2013, 21(6):1525-1550.
- [3] Dantzer, Robert, Meagher, Mary W, Cleeland, Charles S. Translational approaches to treatment-induced symptoms in cancer patients[J]. Nature Reviews Clinical Oncology, 9(7):414-426.
- [4] Henry D H , Viswanathan H N , Elkin E P , et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.[J]. Supportive Care in Cancer, 2008, 16(7):791-801.
- [5]Cleeland, C S, Fengmin Zhao, Victor T. Chang, et al., The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer, 2013. 119(24): p. 4333-40.
- [6]Basch, E, Deal A M, Dueck A C, et al., Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA, 2017. 318(2):197-198.

- 1
2
3
4 [7] Denis F , Basch E , Septans A L , et al. Two-Year Survival Comparing Web-Based
5
6 Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer[J].
7
8
9 JAMA, 2019, 321(3):306-307.
10
11
12 [8] Tencent (2019), "Tencent Announces 2019 Third Quarter Results," Tencent,
13
14 <[https://cdc-tencent-com-1258344706.image.myqcloud.com/uploads/2019/11/13/8b98062](https://cdc-tencent-com-1258344706.image.myqcloud.com/uploads/2019/11/13/8b98062831f2f28d9cb4616222a4d3c3.pdf)
15
16 [831f2f28d9cb4616222a4d3c3.pdf](https://cdc-tencent-com-1258344706.image.myqcloud.com/uploads/2019/11/13/8b98062831f2f28d9cb4616222a4d3c3.pdf)>.
17
18
19
20
21 [9] Cleeland C S , Mendoza T R , Wang X S , et al. Assessing symptom distress in cancer
22
23 patients : The M. D. Anderson Symptom Inventory. Cancer, 2000, 89(7):1634-1646.
24
25
26 [10] Xin, Shelley, Wang, et al. Chinese version of the M. D. Anderson Symptom Inventory :
27
28 Validation and application of symptom measurement in cancer patients[J]. Cancer, 2004.
29
30
31
32 [11] Lin R M , Xie S S , Yan W J , et al. Factor structure and psychometric properties of the
33
34 Insomnia Severity Index in Mainland China. Social Behavior and Personality: an international
35
36 journal, 2018, 46(2).
37
38
39
40 [12] Guo Hua Z , Ming Zhi X U . Factorial Structure of the Hospital Anxiety and Depression
41
42 Scale in Outpatients with Somatic Disease. Chinese Journal of Clinical Psychology. 2006,
43
44 14(6):591-592.
45
46
47
48 [13] Chen S , Fang Y , Psych H C F , et al. Validation of the nine-item Patient Health
49
50 Questionnaire to screen for major depression in a Chinese primary care population. Asia Pac
51
52 Psychiatry. 2013,5(2):61-68.
53
54
55
56 [14] Luo N , Liu G , Li M , et al. Estimating an EQ-5D-5L Value Set for China. Value in
57
58
59
60

1
2
3
4 Health, 2017, 20(4):662-669.
5
6

7 [15] Liu L , Li S , Wang M , et al. Comparison of EQ-5D-5L health state utilities using four
8
9 country-specific tariffs on a breast cancer patient sample in mainland China. Patient
10
11 Preference & Adherence, 2017, 11:1049-1056.].
12
13

14
15 [16] Tang L, Zhang Y, Pang Y, et al. Validation and Reliability of Distress Thermometer in
16
17 Chinese Cancer Patients. Chin J Cancer Res. 2011,23(1):54-58.
18
19

20
21 [17] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP.
22
23 Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol.
24
25 1982;5(6):649-55.
26
27

28
29 [18] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
30
31 prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis.
32
33 1987; 40(5):373-83.
34
35

36
37 [19] Cleeland CS et al. Levels of symptom burden during chemotherapy for advanced lung
38
39 cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011
40
41 Jul 20;29(21):2859-65.
42
43

44
45 [20] Marandino L, Necchi A, Aglietta M, Di Maio M. COVID-19 Emergency and the Need to
46
47 Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice.
48
49 JCO Oncol Pract. 2020 May 1:OP2000237. doi: 10.1200/OP.20.00237
50
51
52
53


54
55
56
57
58 Figure 1: The flow chart of this study
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2: Peking University Cancer Hospital project case

Figure 3: The screen of platform looked to patients

For peer review only



42 Figure 1 The flow chart of this study


43 90x99mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Peking University Cancer Hospital project case
160x59mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



The screen of platform looked to patients

315x207mm (96 x 96 DPI)